Orthocell (ASX:OCC) was granted a license by the Food and Drug Administration of Thailand to start selling its Remplir nerve repair collagen wrap in the country, according to a Monday Australian bourse filing.
Thailand's nerve repair market has an estimated value of $84 million. It plans to appoint a local on-the-ground specialist distributor.
The firm said it leveraged an expedited registration pathway available for medical devices already approved by the Health Sciences Authority in Singapore.
The firm is considering other potential markets in Asia-Pacific, including Taiwan, Vietnam, Indonesia, and the Philippines.
The company's shares gained about 1% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。